Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cellsMaria Rita Milone, Alfredo Budillon|Cell Death and Disease|2013Cited by 63
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathwaysFrancesca Bruzzese, Alfredo Budillon, Renato Franco et al.|Cell Death and Disease|2013Cited by 57
Abstract 3650: <i>In Vitro and in vivo synergistic anticancer effect of HDAC inhibitor panobinostat (LBH589) plus zoledronic acid in human prostate, breast and multiple myeloma tumor models</i>Monia Rocco, Alfredo Budillon, Francesca Bruzzese et al.|Cancer Research|2010Cited by 0